Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

3(33.3%)

9Total

Phase 1(6)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02052960Phase 2Completed

CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer

Role: lead

NCT03360734Phase 1Completed

Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors

Role: lead

NCT01222637Phase 1Completed

CetuGEX™: Phase 1 Study in Cancer Patients

Role: lead

NCT01222624Phase 1Completed

PankoMab-GEX™: Phase 1 Dose Escalation Study

Role: lead

NCT01354886Phase 1Completed

Single Dose FSH-GEX™ in Healthy Volunteers

Role: lead

NCT01409343Phase 1Completed

TrasGEX™: Phase 1 Study in Cancer Patients

Role: lead

NCT01794208Phase 2Completed

Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®

Role: lead

NCT01477073Phase 1Completed

Multiple Dose FSH-GEX(TM) in Healthy Volunteers

Role: lead

NCT01899599Phase 2Completed

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Role: lead

All 9 trials loaded